LOS ANGELES, Jan. 26 /PRNewswire/ -- De Novo Software(TM), a leading provider of flow cytometry data analysis solutions, announced today an agreement with BD Biosciences to sell De Novo Software's flagship product -- FCS Express(TM) -- to customers in clinical, research and pharmaceutical markets worldwide. BD Biosciences, a segment of BD (Becton, Dickinson and Company) is a pioneer and leader in flow cytometry systems and reagents.
"We look forward to providing BD customers with enhanced flow cytometry data analysis capabilities," said De Novo Software President David Novo. "BD Biosciences and De Novo Software will work together to ensure our customers have a positive support experience and build on the existing BD FACSDiva(TM) software integration capabilities present in FCS Express."
Used today by many leading clinical and research laboratories, FCS Express provides comprehensive analysis capabilities, including advanced and easy-to-use report creation tools, 21 CFR Part 11 data security support, quality control alerts and histogram overlays.
"BD Biosciences is committed to offering comprehensive, innovative solutions to support the work of researchers and clinicians in their efforts to understand disease and improve care," said Andy Last, Vice President, Global Marketing and Strategic Planning, BD Biosciences. "FCS Express is the industry's only third-party analysis software for flow cytometry that is registered with the FDA for IVD use. It meets clinical customer requirements and adds new capabilities that complement BD FACSDiva(TM) software."
Customers will be able to purchase FCS Express through the BD Biosciences sales force, website and catalog.
|SOURCE De Novo Software|
Copyright©2009 PR Newswire.
All rights reserved